|
|
|
| home > white papers > Working Towards a Standardised Identification Solution - PCI Pharma Services |
|
|
 WHITE PAPERS |
|
PCI Pharma Services
|
|
Working Towards a Standardised Identification Solution
|
|
The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the
supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Merck Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
More info >> |
|
 |
White Papers |
 |
|
Overcoming research challenges with Adaptive Trials
PCI Pharma Services
There has been cause for concern within the pharmaceutical industry over
the last five years, regarding increasing research and development
costs, combined with a fall in the number of new drugs brought to
market. In an attempt to overcome this issue there has been a
significant rise in the use of adaptive clinical trial designs, whilst
saving time and money as well as facilitating more effective decision
making. One of the biggest challenges that pharmaceutical companies have
experienced has been delivering compliant clinical trials supplies
across diverse patient populations in the relatively short timeframes
that adaptive trial designs require, remaining focused on ensuring that
patient compliance and product quality is in no way compromised. This
demand has led to the launch of fast response services that support
Research and Development in responding to changing dosing regimens
mid-trial.
More info >> |
|
 |
Industry Events |
 |
8th Clinical Quality Oversight Forum 2017
11-13 October 2017, Sheraton Philadelphia Downtown Hotel, Philadelphia, PA
ExL’s Clinical Quality Oversight Forum continues to live up
to its reputation as an elite gathering of senior-level executives.
More info >> |
|
|
|
